MONTREAL, QUEBEC--(Marketwire - October 06, 2009) - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will be presenting an overview of Theratechnologies at BioContact Quebec, which will take place at the Chateau Frontenac, in Quebec City. At his presentation on Thursday, October 8 at 3:00 p.m., Mr. Rosconi will review the operational accomplishments over the last year and discuss Theratechnologies’ strategy and growth opportunities. BioContact Quebec is a biopharmaceutical partnership symposium attended by over 1,000 participants.
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.
In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.
With a New Drug Application recently filed with the US authorities, Theratechnologies’ growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.
Contacts:
Theratechnologies Inc.
Andrea Gilpin
Vice president, IR & Communications
514-336-7800, ext. 205
communications@theratech.com
